ClinicalTrials.gg
CompletedNCT06742762Updated Jun 8, 2025

A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004

A Phase 1 interventional study of AZD5004 in Renal Impairment, sponsored by AstraZeneca. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-08.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Renal Insufficiency by AstraZeneca — none open to participants now, none under way, none of them phase 3. Renal Insufficiency · AstraZeneca.

Enrollment
21st of 29
16 · median 24
Started
2024
with 5 others
Phase 1
26 of 29
none open now
Registered
26th of 29
by date

Among the 29 studies in Renal Insufficiency by AstraZeneca, this one is the 21st largest by enrollment, is one of 6 that started in 2024, is one of 26 in phase 1, and was the 26th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 29 studies in Renal Insufficiency by AstraZeneca is open now. The open studies under Renal Insufficiency, anywhere →

Who these studies take

Of the 93 Renal Insufficiency studies recruiting now, 49 (53%) set no upper age limit and 19 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Renal Insufficiency by AstraZeneca as a file.
02

Study summary

This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD5004 in male and female participants with severe renal impairment and moderate renal impairment (optional) compared with male and female participants with normal renal function.

Read the detailed description

This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD5004 in male and female participants with severe renal impairment and moderate renal impairment (optional) compared with male and female participants with normal renal function.

Participants will be assigned to the following groups based on eGFR determined at screening by a local laboratory using serum creatinine:

Group 1: Participants with severe renal impairment (eGFR \< 30 mL/min), not on dialysis.

Group 2: Participants with normal renal function (eGFR of ≥ 90 mL/min) matched by sex, age, and body weight on a group level to the impaired participants.

Group 3 (optional): Participants with moderate renal impairment (eGFR ≥ 30 to \< 60 mL/min).

03

Conditions studied

  • Renal Impairment

Browse trials for

Keywords

  • Renal Impairment
  • Healthy participants
  • AZD5004
  • Pharmacokinetics
  • Safety
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18-80 years of age
  • Weight >50kg and between 18-40 kg/m2

For participants with normal renal function:

-Participant must be medically healthy with no significant findings on medical evaluation and an ≥90 ml/min at screening.

For participants with renal impairment:

Group 1 (severe) must have an eGFR \<30 ml/min and Group 3 (moderate) must have an eGFR 30 to \<60 ml/min based on CKD-EPI calculations for at least 6 months prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  • Poorly controlled diabetes mellitus ( >10% at screening or recent history of diabetic ketoacidosis or symptomatic hypoglycemia).
  • Unwillingness to use adequate
  • Uncontrolled hypertension or hypotension.
  • Positive screening for , , or
  • Presence of unstable systemic disease or psychologic conditions. Abnormal laboratory values to include but not limited to liver function tests (thresholds differ for renal impairment and health controls)
  • Any change in baseline medication within 2 weeks of planned study initiation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Group 1

    Participants with severe renal impairment will receive a single oral dose of AZD5004 under fasted conditions.

    Drug: AZD5004

  • Experimental
    Group 2

    Participants with normal renal function will receive a single oral dose of AZD5004 under fasted conditions.

    Drug: AZD5004

  • Experimental
    Group 3 (Optional)

    Participants with moderate renal impairment will receive a single oral dose of AZD5004 under fasted conditions.

    Drug: AZD5004

Interventions

  • Dose 1

    Also known as: ECC5004, Dose 1

06

What researchers measure

Primary outcomes

  1. AUCinf

    Area under the concentration-time curve from zero to infinity

    Time frame: Day 1 to Day 5

  2. AUClast

    Area under the concentration-time curve from zero to the last measurable concentration

    Time frame: Day 1 to Day 5

  3. Cmax

    Maximum observed plasma concentration

    Time frame: Day 1 to Day 5

Secondary outcomes

  1. Tmax

    Time to reach maximum observed plasma concentration

    Time frame: Day 1 to Day 5

  2. PK parameter t1/2λz

    Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve

    Time frame: Day 1 to Day 5

  3. PK parameter CL/F

    Apparent total body clearance of drug from plasma after extravascular administration

    Time frame: Day 1 to Day 5

  4. PK parameter CLNR/F

    non-renal clearance of drug from plasma after oral administration

    Time frame: Day 1 to Day 5

  5. PK parameter Vz/F

    Apparent volume of distribution during the terminal phase after extravascular administration

    Time frame: Day 1 to Day 5

  6. PK parameter CLr

    Renal clearance of the drug from plasma

    Time frame: Day 1 to Day 5

  7. PK parameter Ae

    Cumulative amount of unchanged drug excreted into the urine

    Time frame: Day 1 to Day 5

  8. fe

    Fraction of the drug excreted into the urine

    Time frame: Day 1 to Day 5

Other outcomes

  1. Number of participants with adverse events (AEs)

    To assess the safety and tolerability of a single oral dose of AZD5004 for participants with severe and moderate (optional) renal impairment and those with normal renal function

    Time frame: Day 1 to Day 10

  2. Number of participants with abnormal Vital signs, abnormal ECGs, and abnormal physical examination findings

    To assess the safety and tolerability of a single oral dose of AZD5004 for participants with severe and moderate (optional) renal impairment and those with normal renal function

    Time frame: Day 1 to Day 5

  3. Number of participants with abnormal laboratory tests results

    To assess the safety and tolerability of a single oral dose of AZD5004 for participants with severe and moderate (optional) renal impairment and those with normal renal function

    Time frame: Day 1 to Day 5

07

Study locations

3 sites
  • Research Site
    Miami Lakes, Florida 33014, United States
  • Research Site
    Orlando, Florida 32808, United States
  • Research Site
    Orlando, Florida 32809, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Apr 2025, 4 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 4 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2024
First posted
Dec 19, 2024
StartActual
Dec 17, 2024
Primary completionActual
Apr 20, 2025
CompletionActual
Apr 20, 2025
Last update
Jun 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06742762
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 19, 2024
Start date
Dec 17, 2024
Primary completion
Apr 20, 2025
Completion
Apr 20, 2025
Last update
Jun 8, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elecoglipron

Start the discussion